- 286studies in the library match, of 29,380
- 133name it in the title
- 2014–2026years published
- 269peer-reviewed articles
The query: title or abstract mentions "lecanemab", "Leqembi" or "BAN2401", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Lecanemab is a monoclonal antibody given by infusion that binds to soluble forms of amyloid-beta and clears amyloid plaques from the brain. Its approval rests on a phase 3 trial in people with mild cognitive impairment or mild dementia due to Alzheimer's who had amyloid confirmed by a scan or spinal fluid test.
The two questions the papers argue over are how much the slowing of decline matters to a patient and family, and how to weigh it against amyloid-related imaging abnormalities (ARIA), the brain swelling or small bleeds the drug can cause. The sections below count the studies on each.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 286 matched records are quoted; each links to its study page and from there to the paper.
“In the analysis subgroup, the most common adverse reactions for lecanemab were infusion-related reactions (26 %), ARIA-H (13 %), fall (11 %), headache (11 %), and ARIA-E (9 %).”
“Methods BAN2401-G000-201 aimed to establish the effective dose 90% (ED90), defined as the simplest dose that achieves ≥90% of the maximum treatment effect.”
“Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD.”
“Statistically significant improvements in health-related quality of life were observed with lecanemab in ApoE4 heterozygous participants and in those aged 65-74 years.”
“Results A total of 1795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo.”
“The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and is administered intravenously.”
“Results Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core + OLE) were included.”
“Results A total of four randomized controlled trials were included, involving 3,108 AD patients (1,695 lecanemab groups and 1,413 placebo groups) to synthesize evidence.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 22 |
| Randomised controlled trial | 4 |
| Other clinical trial | 35 |
| Cohort or longitudinal study | 18 |
| Case-control study | 2 |
| Cross-sectional study | 3 |
| Other recorded design | 18 |
| No design recorded | 184 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 64 | |
| 2025 | 111 | |
| 2024 | 53 | |
| 2023 | 42 | |
| 2022 | 8 | |
| 2021 | 3 | |
| 2020 | 1 | |
| 2019 | 0 | |
| 2018 | 1 | |
| 2017 | 0 | |
| 2016 and earlier | 3 |
Other counts within the matched set
| Peer-reviewed articles | 269 |
| Marked open access in the record | 140 |
| Rated "high" evidence strength in alzhub's summary | 47 |
| Rated "moderate" evidence strength in alzhub's summary | 40 |
| Rated "low" evidence strength in alzhub's summary | 191 |
| No evidence-strength rating | 8 |
| Records stating a participant count | 61 |
| Median participants (those records) | 294 |
| Largest participant count | 1,307,937 |
Within the 286 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that also discuss ARIA | 148 | the abstract also contains "ARIA" or "amyloid-related imaging abnormalities" |
| …that also mention Clarity AD, the phase 3 trial | 26 | the abstract also contains "Clarity AD" |
| …that also mention cost or price | 36 | the abstract also contains "cost", "price" or "cost-effective" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
- Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
- Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
- Lecanemab in Early Alzheimer's Disease
- Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review
- Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease
- Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Systematic reviews and meta-analyses in the set
22 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
- The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials
- Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis
- Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
- Use of lecanemab for the treatment of Alzheimer's disease: A systematic review
Newest matched studies
- Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA
- When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
- Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)
- Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)
- Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Alzheimer's research & therapy | 14 |
| Alzheimer s & Dementia | 10 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 10 |
| Journal of Alzheimer's disease : JAD | 10 |
| The journal of prevention of Alzheimer's disease | 8 |
Questions
- What is lecanemab?
- A monoclonal antibody against amyloid-beta, given by intravenous infusion, approved in the United States for people with mild cognitive impairment or mild dementia due to Alzheimer's disease who have confirmed amyloid in the brain. Its brand name is Leqembi.
- What is ARIA?
- Amyloid-related imaging abnormalities: swelling (ARIA-E) or small bleeds (ARIA-H) seen on MRI in some people treated with anti-amyloid antibodies. Most cases found in trials caused no symptoms, some caused symptoms, and a few were serious, which is why treatment includes scheduled MRI scans.
- How many studies on lecanemab (leqembi) does alzhub hold?
- 286 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "lecanemab", "Leqembi" or "BAN2401""; 133 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 22 systematic review or meta-analysis, 4 randomised controlled trials, 35 other clinical trials, 18 cohort or longitudinal studys, 2 case-control studys, 3 cross-sectional studys; 184 record no design.
- What is the most recent study in the set?
- "Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA" (bioRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Alzheimer's research & therapy (14); Alzheimer s & Dementia (10); Alzheimer's & dementia : the journal of the Alzheimer's Association (10), counted across the matched records.
Read on
- Anti-amyloid antibodies: what the trials showedThe pivotal trial results and ARIA rates from each FDA label, in plain numbers.
- Lecanemab and donanemab: do they work?A short answer page on the two approved antibodies.
- Getting the drugs coveredHow Medicare covers the new drugs and how to appeal.
- ARIA: brain swelling and bleedsThe side effect both drugs share.